Our results indicate that KRAS‐TOPK axis contributes to the progression of NSCLC and targeting this axis could synergize with anticancer effect of the existing chemotherapeutics for NSCLC treatment. The gene discussed is PBK; the disease is non-small cell lung carcinoma.